Challenger Limited (ASX:CGF)

Verve Therapeutics Ratios and Metrics

Market cap in millions AUD. Fiscal year is July - June.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Market Capitalization	5,632	4,802	4,443	4,652	3,639	3,168
Market Cap Growth	-7.86%	8.07%	-4.49%	27.84%	14.87%	-21.24%
Enterprise Value	12,644	11,101	9,500	9,475	10,252	9,420
PE Ratio	39.16	36.97	25.92	18.34	6.14	-
PS Ratio	1.59	1.47	1.73	-14.08	1.09	1.75
PB Ratio	1.46	1.24	1.14	1.17	0.95	0.98
P/FCF Ratio	16.52	4.58	3.46	1.87	1.42	6.66
P/OCF Ratio	16.47	4.57	3.44	1.87	1.41	6.53
EV/Sales Ratio	3.56	3.39	3.69	-	3.08	5.19
EV/EBITDA Ratio	6.92	6.79	8.11	-	9.39	-
EV/EBIT Ratio	7.00	6.82	8.15	-	9.43	-
EV/FCF Ratio	37.08	10.58	7.41	3.82	4.00	19.81
Debt / Equity Ratio	1.97	1.93	1.60	1.55	1.76	2.57
Debt / EBITDA Ratio	4.22	4.56	5.33	-	6.14	-
Debt / FCF Ratio	22.20	7.14	4.89	2.49	2.63	17.57
Quick Ratio	3.35	1.79	1.79	1.70	1.45	1.16
Current Ratio	3.48	1.83	1.87	1.78	1.55	1.22
Asset Turnover	0.11	0.10	0.09	-	0.11	0.07
Return on Equity (ROE)	3.78%	3.45%	4.54%	6.77%	16.74%	-12.26%
Return on Assets (ROA)	3.31%	3.16%	2.40%	-0.71%	2.33%	-0.54%
Return on Capital (ROIC)	9.92%	9.44%	7.16%	-2.05%	6.13%	-1.34%
Earnings Yield	2.59%	2.71%	3.86%	5.45%	16.28%	-13.13%
Earnings Yield	2.59%	2.71%	3.86%	5.45%	16.28%	-13.13%
FCF Yield	6.05%	21.86%	28.87%	53.39%	70.45%	15.01%
Dividend Yield	3.55%	3.96%	4.02%	3.77%	4.29%	4.67%
Payout Ratio	122.91%	115.01%	71.47%	52.70%	10.80%	-
Buyback Yield / Dilution	-0.66%	-0.52%	19.98%	5.08%	-50.86%	22.58%
Total Shareholder Return	2.87%	3.44%	24.00%	8.85%	-46.57%	27.25%

Source: S&P Global Market Intelligence. Insurance template. Financial Sources.